14 results about "Sublingual Tablet" patented technology

A sublingual tablet and application thereof in desensitization therapy drug are provided. The sublingual tablet is a low-dose allergen sublingual tablet. The sublingual tablet includes freeze-dried powder of allergen protein, lactose, mannitol, low substituted hydroxypropyl cellulose, low moisture microcrystalline cellulose, and magnesium stearate. The freeze-drying process is adopted to obtain the freeze-dried powder of allergen protein, and the powder direct compression technology is adopted to obtain the sublingual tablet of allergen protein. The low-dose sublingual tablet has excellent properties, including appearance, hardness, tablet weight variation, disintegration time, taste, and uniformity of content, in particular has outstanding advantages in disintegration time, uniformity of content, stability, and preparation process, and has an industrial application prospect.

The invention belongs to the technical field of pharmaceutical preparations, and particularly relates to sublingual lozenges of progesterone and analogues thereof as well as a preparation method and application of the sublingual lozenges. Specifically, a novel sublingual administration dosage form which is more suitable for being absorbed by a human body is designed according to physicochemical properties of progesterone and analogues thereof. The sublingual lozenge is composed of a main drug, a filler, a disintegrating agent, a mucous membrane promoter, a flavoring agent, a lubricant and the like. The sublingual lozenge is quickly disintegrated under the action of saliva, is quickly absorbed through tongue mucosa, takes effect quickly, avoids the first-pass effect, improves the bioavailability, and is suitable for various clinical scenes needing quick and efficient progestational hormone support.

The present disclosure relates to sublingual tablets and application thereof in desensitization therapy drug. The sublingual tablet of the present disclosure is a low-dose allergen sublingual tablet. The sublingual tablet comprises freeze-dried powder of allergen protein, lactose, mannitol, low substituted hydroxypropyl cellulose, low moisture microcrystalline cellulose, and magnesium stearate. The present disclosure adopts the freeze-drying process to obtain the freeze-dried powder of allergen protein, and adopts the powder direct compression technology to obtain the sublingual tablet of allergen protein. The low-dose sublingual tablet of the present disclosure has excellent properties, including appearance, hardness, tablet weight variation, disintegration time, taste, and uniformity of content, in particular has outstanding advantages in disintegration time, uniformity of content, stability, and preparation process, and has an industrial application prospect.

Sublingual Semaglutide compositions may comprise both Semaglutide or a salt thereof and a gastric peptide or salt thereof, in combination. The use of a gastric peptide mitigates gastrointestinal side effects of Semaglutide. A weight loss regimen comprises administration of sublingual Semaglutide compositions in the physical form of sublingual tablets. In preferred embodiments, each sublingual Semaglutide tablet provides about 500 mcg Semaglutide or 750 mcg Semaglutide in combination with 300 mcg of gastric peptide, with the gastric peptide preferably comprising Body Protection Compound-157 (BPC-157). Sublingual administration of Semaglutide finds use in suppressing appetite, losing weight, and maintaining a desired personal appearance.

The present application relates to a sublingual tablet of nicergoline and a preparation method thereof, the sublingual tablet of nicergoline comprising nicergoline and pharmaceutically acceptable excipients; the pharmaceutically acceptable excipients comprise organic acid, diluent, disintegrant and lubricant. In the sublingual tablet of nicergoline, the organic acid as a cosolvent and the combination with nicergoline can increase the cumulative dissolution rate and dissolution rate of nicergoline, and improve the bioavailability and pharmacodynamic persistence of nicergoline. At the same time, the sublingual tablet of nicergoline can avoid liver first-pass effect, and has the advantages of convenient use and no need of water for administration.

This invention discloses a method for constructing a light anesthesia lozenge administration animal model, belonging to the field of biotechnology. The method involves administering propofol to animals, and after the righting reflex disappears, administering a lozenge to obtain a light anesthesia lozenge administration animal model. This method has good reproducibility, the experimental animals exhibit good tolerance, and it accurately simulates the clinical lozenge administration process, solving the key problem of discrepancies between the gavage administration route and clinical practice in traditional lozenge animal experiments.

The invention relates to the technical field of medicine, in particular to an ethanesulfonic acid nintedanib sublingual tablet and a preparation method thereof.The ethanesulfonic acid nintedanib sublingual tablet contains ethanesulfonic acid nintedanib, a carrier material, a filling agent, a disintegrating agent, a flavoring agent and a lubricating agent, and the ethanesulfonic acid nintedanib sublingual tablet is prepared by setting the specific proportion of the raw materials and the auxiliary materials. Compared with an original research medicine, namely a nintedanib ethanesulfonate soft capsule, the problem that the bioavailability is low due to the liver first-pass effect is effectively solved, the medicine provided by the invention is good in taste, excellent in stability, rapid in disintegration and rapid in dissolution rate, and each detection item meets the quality standard. And meanwhile, the clinical use compliance of a patient is also improved.

The invention relates to the technical field of pharmaceutical preparations, in particular to a Naodesheng sublingual tablet and a preparation method thereof. The Naodesheng sublingual tablet provided by the invention is prepared from 160 to 240 parts of Naodesheng thick paste, 30 to 50 parts of a first adhesive, 30 to 50 parts of a second adhesive, 15 to 30 parts of a third adhesive, 180 to 300 parts of a diluent, 70 to 90 parts of a first mucous membrane absorption enhancer, 30 to 50 parts of a second mucous membrane absorption enhancer, 120 to 180 parts of a mucous membrane adhesive, 30 to 50 parts of an osmotic pressure accelerant, 30 to 50 parts of a flow aid, and 3 to 4 parts of ligusticum wallichii-safflower volatile oil and a lubricant. According to the Naodesheng sublingual tablet, the content of active ingredients such as ferulic acid and general flavone is increased, and the active ingredients are directly absorbed into blood through oral mucosa and can quickly play a whole body role, so that the blood flow state of heart and cerebral vessels can be quickly improved, the formation of thrombus is reduced, the thrombolysis effect is improved, and the ischemic state of the heart and cerebral vessels can be quickly got rid of.

The present invention relates to pharmaceutical compositions comprising one or more cannabinoids and optionally one or more pharmaceutically acceptable carriers, diluents, adjuvants, excipients, or any combination thereof. In particular, the compositions of the present invention comprise a mixture of THC and CBD in varying proportions and are preferably in the form of sublingual tablets, sublingual drops, or soft gelatin capsules.

Sublingual Semaglutide compositions may comprise both Semaglutide or a salt thereof and a gastric peptide or salt thereof, in combination. The use of a gastric peptide mitigates gastrointestinal side effects of Semaglutide. A weight loss regimen comprises administration of sublingual Semaglutide compositions in the physical form of sublingual tablets. In preferred embodiments, each sublingual Semaglutide tablet provides about 500 mcg Semaglutide or 750 mcg Semaglutide in combination with 300 mcg of gastric peptide, with the gastric peptide preferably comprising Body Protection Compound-157 (BPC-157). Sublingual administration of Semaglutide finds use in suppressing appetite, losing weight, and maintaining a desired personal appearance.

Provided are a nicergoline sublingual tablet and a preparation method therefor. The nicergoline sublingual tablet comprises nicergoline and a pharmaceutically acceptable auxiliary material; the pharmaceutically acceptable auxiliary material comprises an organic acid, a diluent, a disintegrant and a lubricant. In the nicergoline sublingual tablet, the organic acid is used as a co-solvent, and the compounding of same with nicergoline can increase the cumulative dissolution rate and dissolution speed of nicergoline, thereby improving the bioavailability and efficacy durability of nicergoline. The nicergoline sublingual tablet can avoid the hepatic first-pass effect, and has the advantages of convenient use and no need to be taken with water.

The present application provides a sublingual tablet composition of lumeritopine tosylate and a preparation method thereof. The sublingual tablet composition of lumeritopine tosylate comprises the following ingredients by weight percentage: lumeritopine tosylate 2% to 15% (1.4 mg / tablet to 10 mg / tablet), filler 15% to 75%, disintegrant 2% to 10%, surfactant 0.1% to 10%, lubricant 0.5% to 2%, glidant 0.5% to 2%, and flavoring agent 0.5% to 2%. The sublingual tablet composition is prepared by direct compression of powder. The sublingual tablet composition has good taste, does not irritate mucosa, is rapidly absorbed under the tongue, and has significantly higher bioavailability than ordinary oral tablets.

The present invention relates to the field of pharmaceutical preparations, in particular to sublingual tablets and their application in hyposensitization therapy. [Solution] The sublingual tablet of the present invention is a low-dose allergen sublingual tablet, containing a freeze-dried powder of an allergen protein, as well as lactose, mannitol, low-substituted hydroxypropyl cellulose, low-moisture microcrystalline cellulose, and magnesium stearate. The allergen protein sublingual tablet of the present invention is prepared by freeze-drying the freeze-dried powder of the allergen protein to produce tablets using direct powder compression molding. The low-dose sublingual tablet of the present invention is excellent in various parameters such as appearance, hardness, tablet weight difference, disintegration time, swallowing sensation, and content uniformity, and particularly has significant advantages in disintegration time, content uniformity, stability, and manufacturing process, making it worthy of industrial application.

The application discloses cilostazol dextrophan sublingual tablets and a preparation method thereof. The application effectively solves the technical bottleneck that cilostazol cannot be quickly dissolved due to poor solubility by optimizing the types and proportions of excipients; and by creatively adding sodium bicarbonate and citric acid, the dual technical targets of 'fast dissolution + high hardness' are unexpectedly achieved, the bioavailability of cilostazol is significantly improved, and the drug effect of cilostazol can be quickly exerted within the golden treatment period of acute cerebral stroke. Meanwhile, the drug composition process is good in feasibility, the prepared sublingual tablets are excellent in disintegration performance, can adapt to the drug administration needs of patients with dysphagia, completely meet the clinical application and pharmaceutical quality standards, and have significant clinical value and industrialization potential.